Mavyret (glecaprevir, pibrentasvir)
Reviewed by: HU Medical Review Board | Last reviewed: May 2023 | Last updated: May 2023
Mavyret® (glecaprevir, pibrentasvir) is a combination medicine used to treat hepatitis C virus (HCV). It is approved for use in children ages 3 and older and adults.1,2
Mavyret is used to treat people with:1,2
- All 6 genotypes (strains) of HCV
- Chronic HCV without cirrhosis
- Chronic HCV with compensated cirrhosis
- HCV genotype 1 infection who have been previously treated with either an NS5A inhibitor or an NS3/4A protease inhibitor, but not both
What are the ingredients in Mavyret?
The active ingredients in Mavyret are glecaprevir and pibrentasvir.1
How does Mavyret work?
The active ingredients in Mavyret work in different ways to attack the hepatitis C virus:1
- Glecaprevir is an inhibitor of the protease HCV NS3/4A. HCV needs this enzyme to grow. Blocking this enzyme helps stop its growth.
- Pibrentasvir inhibits HCV NS5A. This is a key protein HCV needs to multiply. Blocking this protein helps stop HCV growth.
Mavyret can reduce the HCV in the body to undetectable levels.1
What are the possible side effects of Mavyret?
The most common side effects of Mavyret include headache and fatigue.1
Mavyret has a boxed warning, the strictest warning from the U.S. Food and Drug Administration (FDA). This is because it may worsen or reactivate hepatitis B infection during or after treatment. This may cause serious liver damage, liver failure, or death. People with current or past hepatitis B infection should be monitored during and after treatment with Mavyret. Some may also need to be treated for hepatitis B. Before starting treatment with Mavyret, your doctor should check you for hepatitis B infection.1,2
These are not all the possible side effects of Mavyret. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Mavyret.
Things to know about Mavyret
Mavyret should not be used by people who:1,2
- Take the drugs rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®) or atazanavir (Reyataz®)
- Have moderate or severe hepatic impairment (Child-Pugh B or C)
Before starting Mavyret, tell your doctor if you have:1,2
- A current or previous hepatitis B virus infection
- Any liver problems other than HCV
There is not enough data to know if Mavyret is safe to take while pregnant or breastfeeding. Before starting Mavyret, tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.1
Mavyret may interact with other drugs and supplements. Before beginning treatment for HCV, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.
For more information, read the full prescribing information of Mavyret.